Recent 8-K filings for ODTX
Highest-materiality recent filing
Odyssey Therapeutics raises $25M from TPG affiliate in private placement concurrent with IPO at $18/share
- Private placement of 1,388,889 shares of common stock at $18.00 per share for total proceeds of $25,000,002.
- Placement closed concurrently with the IPO on May 11, 2026; shares are registrable under existing Investor Rights Agreement.
-
Odyssey Therapeutics Q2 2026 net loss $52.8M; cash $433.1M; OD-001 data at UEG Week
Net loss $52.8M for Q2 2026 vs $41.2M in Q2 2025; adjusted net loss (non-GAAP) $38.4M.
-
Odyssey Therapeutics posts June 2026 corporate presentation on website
Presentation furnished as Exhibit 99.1; no specific financial or clinical updates provided in filing text.
-
Odyssey Therapeutics Q1 net loss $38.3M; pro-forma cash $464M; positive OD-001 data
Cash and securities $175.7M at Mar 31, 2026; pro-forma cash $464.4M after IPO net proceeds of $288.7M.
-
Private placement of 1,388,889 shares of common stock at $18.00 per share for total proceeds of $25,000,002.
Materiality & sentiment trend
Max materiality 0.65 · Median 0.57 · Most common event earnings